ClinicalTrials.gg
CompletedNCT00884000Updated Jul 17, 2012

A Study of Zomacton in Children With Growth Hormone Deficiency

A Phase 3 interventional study of Genotropin and Zomacton in Growth Hormone Deficiency, sponsored by Ferring Pharmaceuticals. Completed at 43 sites in 7 countries. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2012-07-17.

Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
3 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
13th of 60
165 · median 66
Started
2010
with 3 others
Phase 3
23 of 60
2 open now
Registered
28th of 60
by date

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 13th largest by enrollment, is one of 4 that started in 2010, is one of 23 in phase 3, and was the 28th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

This trial is set up to compare Zomacton to Genotropin for the treatment of growth hormone deficiency in children. The children will be treated for 1 year. Half of the patients will be treated with Genotropin and half with Zomacton. During this time they will be dosed every day by themselves or their parents at home in the evening. There will be 138 patients in the trial from age 3 to age 11. The patients cannot have been treated before with growth hormone and the patients must have a proven growth hormone deficiency, this will be shown by a specific test that will be performed before the trial in the local clinic and once during the trial. During the time of the treatment the patients will come to visit the clinic every 3 months. At these visits their heights will be measured, blood samples will be taken, physical examinations will be performed and questions about their health will be asked. At 2 times in the trial they will have a hand x-ray taken to measure the bone age. At the end of the trial the patients will stop the treatment and continue on one of the marketed products available to treat growth hormone deficiency.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
3 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Children aged ≤3yrs old and not above 10 yrs for girls or 11 yrs for boys
  3. Idiopathic growth hormone deficiency confirmed during the pre-screening period by a standard GH stimulation test (defined as peak level of \<10ng/ml pr lower if so required by the country specific board(s)
  4. Height SDS \<-2 SD of ref value for CA
  5. Height velocity SDSCA ≤ 0 SD of ref value for at lease 6 months prior to pre-screening
  6. Height recorded for at least 6 months but not more than 18 months of pre-screening
  7. The difference between CA-BA≥ 1
  8. A positive locally performed GH stimulation test (defined as a peak plasma level of\<9ng/ml or lower if so required by the country specific board(s)) prior to the pre-screening

Exclusion criteria

Exclusion Criteria:

  1. BA above 9 yrs for girls and 10 yrs for boys
  2. Puberty Tanner stage >1
  3. Weight \<12 Kg at screening
  4. Any prior treatment with GH
  5. Closed epiphysis
  6. Any diagnosed or suspected syndrome (e.g. Silver -Russell, Turner's or seckel syndrome) which possibly could affect growth
  7. Any other diagnosed or suspected endocrine or metabolic disorder
  8. Any diagnosed or suspected sever chronic disease
  9. Clinical signs of dysmorphic features, malformations or mental retardations
  10. Growth failure due to other disorders
  11. Previous or present use of drugs that could interfere with GH treatment (e.g. )
  12. Diagnosed malignant disease
  13. Any abnormal CS lab results that requires further investigation
  14. Receipt of an drug within the last 28 days preceding screening or longer if considered possible to influence the outcome of the current trial
  15. Any knowledge of to somatropin or any of the of Zomacton or Genotropin
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Active comparator
    1

    Drug: Genotropin

  • Experimental
    2

    Drug: Zomacton

Interventions

06

What researchers measure

Primary outcomes

  1. Height Velocity

    Time frame: 12 months

Secondary outcomes

  1. Height SDS

    Time frame: 12 months

  2. Height velocity SDS

    Time frame: 12 months

  3. Change in IGF-1 and IGFBP-3

    Time frame: 12 months

  4. BA (Bone Age)

    Time frame: 12 months

  5. Anti-hGH AB

    Time frame: 12 months

  6. AE and tolerability

    Time frame: 12 months

  7. CS Changes in safety lab, physical examination and vital signs

    Time frame: 12 months

07

Study locations

43 sites
  • Semmelweiss University, 1st dept of paediatrics
    Budapest, Hungary
  • Szent Janos Kh Budai
    Budapest, Hungary
  • Petz Country Teaching Hospital
    Gyor, Hungary
  • University of Szeged
    Szeged, Hungary
  • Markusovszkty Teaching Hospital
    Szombathely, Hungary
  • Associates in Clinical Endocrinology Education and Research (ACEER)
    Chennai, India
  • Apollo Hospitals
    Hyderabad, India
  • TOTALL Diabetes Hormone Institute
    Indore, India
  • KEM Hospital
    Mumbai, India
  • Prince Aly Khan Hospital
    Mumbai, India
  • Endocare Clinic
    Nasik, India
  • Jehangir Clinical Development Centre Pvt. Ltd., Jehangir Hospital
    Pune, India
  • Health & Research Centre
    Trivandrum, India
  • Haemek Medical Center
    Afula, Israel
  • Soroka University Medical Center
    Beer Sheva, Israel
  • Western Galilee Medical Center
    Nahariya, Israel
  • Schneider Children's Medical Center of Israel
    Petach Tikva, Israel
  • Edmond and Lily Safra Children's hospital - The Chaim Sheba Medical Center
    Ramat Gan, Israel
  • Kaplan Medical Center
    Rehovot, Israel
  • Dana Children's Hospital - Tel-Aviv Sourasky Medical Center
    Tel Aviv, Israel
  • Wojewódzki Szpital Dziecięcy im. J.Brudzińskiego w Bydgoszczy
    Bydgoszcz, Poland
  • Uniwersyteckie Centrum Kliniczne, Gdańsk
    Gdansk, Poland
  • Uniwersytecki Szpital Dziecięcy w Krakowie
    Krakow, Poland
  • SPSK nr.1 im. Prof. T. Sokołowskiego PAM Szczecin
    Szczecin, Poland
  • Societatea Civila Medicala "Dr. Paveliu"
    Bucuresti, Romania
  • Spitalul Clinic Municipal "Filantropia"
    Craiova, Romania
  • Spitalul Clinic Judetean de Urgenta "Sf. Spiridon"
    Iasi, Romania
  • Spitalul Clinic Judetean Mures
    Targu Mures, Romania
  • Paediatric Endocrinology/Medicali's SRL
    Timisoara, Romania
  • Spitalul Clinic pentru Copii Louis Turcanu
    Timisoara, Romania
  • State Educational Institution of Higher Professional Education "Kazan State Medical University of ROSZDRAV
    Kazan, Russian Federation
  • Federal State Institution
    Moscow, Russian Federation
  • Russian Medical Academy of Post-graduate Education
    Moscow, Russian Federation
  • Saint-Petersburg State Health Care Institution
    Saint Petersburg, Russian Federation
  • State Educational Institution for Higher Professional Education
    Saratov, Russian Federation
  • State Educational Institution of Higher Professional Education "Siberian State Medical University of ROSZDRAV
    Tomsk, Russian Federation
  • Donetsk Regional Clinical Children's Hospital
    Donetsk, Ukraine
  • Ivano-Frankivsk Regional Children Clinical Hospital
    Ivano-Frankivsk, Ukraine
  • Kharkiv Regional Clinical Children's Hospital
    Kharkiv, Ukraine
  • Institute of Endocrinology and Metabolism
    Kiev, Ukraine
  • Ukrainian Children's Specialized Clinical Hospital
    Kiev, Ukraine
  • Odessa National Medical University - (Located at Odessa Region Children's Clinical Hospital)
    Odessa, Ukraine
  • Zaporizhzhya Regional Paediatric Hospital
    Zaporizhya, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Jun 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2009
First posted
Apr 20, 2009
Start
Jan 2010
Primary completionActual
Jun 2012
CompletionActual
Jul 2012
Last update
Jul 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00884000
Responsible party
Sponsor
First posted
Apr 20, 2009
Start date
Jan 2010
Primary completion
Jun 2012
Completion
Jul 2012
Last update
Jul 17, 2012

Study contacts

Clinical Development Support
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion